Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Ischemic Stroke due to Postmenopausal Hormone Therapy | Zendy

Jacques E. Rossouw | Zendy; Karen Johnson | Zendy; Mary Pettinger | Zendy; Mary Cushman | Zendy; Per Morten Sandset | Zendy; Lewis H. Kuller | Zendy; Frits R. Rosendaal | Zendy; Jan Rosing | Zendy; Sylvia Wasserthal-Smoller | Zendy; Lisa W. Martin | Zendy; JoAnn E. Manson | Zendy; Kamakshi Lakshminarayan | Zendy; José G. Merino | Zendy; J.A. Lynch | Zendy

Open Access

Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Ischemic Stroke due to Postmenopausal Hormone Therapy

Author(s) -

Jacques E. Rossouw,

Karen Johnson,

Mary Pettinger,

Mary Cushman,

Per Morten Sandset,

Lewis H. Kuller,

Frits R. Rosendaal,

Jan Rosing,

Sylvia Wasserthal-Smoller,

Lisa W. Martin,

JoAnn E. Manson,

Kamakshi Lakshminarayan,

José G. Merino,

J.A. Lynch

Publication year - 2012

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.111.643072

Subject(s) - medicine , hormone therapy , stroke (engine) , tissue factor pathway inhibitor , activated protein c resistance , risk factor , ischemic stroke , endocrinology , gastroenterology , tissue factor , ischemia , breast cancer , thrombosis , cancer , mechanical engineering , factor v leiden , venous thrombosis , engineering , coagulation

To test whether changes in plasma tissue factor pathway inhibitor (TFPI) levels or activated protein C resistance (normalized activated protein C resistance ratio [nAPCsr]) modify the increased risk of ischemic stroke due to postmenopausal hormone therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research